Business Wire, Nov. 12, 2006http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061113005514&newsLang=en CAMBRIDGE, Mass.--Results from the Phase II study of ALTU-238 will be presented at the Third International Congress of the Growth Hormone Research Society which is taking place this week in Kobe, Japan. ALTU-238 is being developed as a once-per-week formulation of human growth hormone. Lead investigator Dr. Randall J. Urban, Chief of Medicine at The University of Texas Medical Branch in Galveston said, “The standard treatment for growth hormone deficiency typically requires multiple injections per week, a regimen that can be inconvenient and painful, which may lead to poor patient compliance. This promises to improve patient quality of life with better dosing ... we believe it represents a significant milestone in the treatment of growth hormone disorders.”